AAP
MPLT

Arax Advisory Partners’s MapLight Therapeutics MPLT Stock Holding History

Arax Advisory Partners’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Buy
33
+28
+560% +$805 ﹤0.01% 4910
2026
Q1 		$20 Buy
+5
New +$89 ﹤0.01% 3719

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's MPLT Position: Q2 2026 in Review

Arax Advisory Partners increased its MapLight Therapeutics (MPLT) stake by 560% in Q2 2026, buying an estimated $805 and bringing the position to 33 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #4910.

Arax Advisory Partners first reported a position in MPLT in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Arax Advisory Partners held 33 shares of MapLight Therapeutics worth $1.18K as of Q2 2026.
  • Arax Advisory Partners bought 28 MapLight Therapeutics shares in Q2 2026, an estimated $805.
  • MapLight Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4910 holding.
  • Arax Advisory Partners first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.